Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.41 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 5/20 | 0.37 |
| ▸ | JAK2 | O60674 | 2/20 | 0.35 |
| ▸ | JAK3 | P52333 | 2/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | AHR | P35869 | 2/20 | 0.35 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.35 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | EIF4E | P06730 | 1/20 | 0.35 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17102325 | 0.79 | FLT3 (0.41) | FLT3IRAK4IRAK1PRMT5WDR77 | |
| SCHEMBL2178803 | 0.79 | ALDH1A1 (0.45) | FLT3IRAK4IRAK1PRMT5WDR77 | |
| SCHEMBL23478409 | 0.79 | PRMT5 (0.42) | FLT3IRAK4IRAK1PRMT5WDR77 | |
| SCHEMBL2177773 | 0.75 | CYP11B2 (0.42) | FLT3IRAK4IRAK1PRMT5WDR77 | |
| SCHEMBL9941943 | 0.73 | TGFBR1 (0.44) | FLT3IRAK4IRAK1PRMT5WDR77 | |
| SCHEMBL2049652 | 0.72 | TGFBR1 (0.43) | FLT3IRAK4IRAK1PRMT5WDR77 | |
| SCHEMBL18041661 | 0.72 | PIK3CA (0.47) | FLT3TGFBR1AHR | |
| Lithium Ion SCHEMBL2049649 | 0.71 | TGFBR1 (0.43) | FLT3IRAK4IRAK1PRMT5WDR77 | |
| SCHEMBL2176764 | 0.71 | EGLN2 (0.39) | FLT3IRAK4IRAK1PRMT5WDR77 | |
| SCHEMBL14756580 | 0.70 | CSF1R (0.41) | FLT3IRAK4IRAK1PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12258365-B2 | Organophosphorus-substituted compounds as c-MET inhibitors and therapeutic uses thereof | BETA PHARMA, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| EP-3893872-B1 | ORGANOPHOSPHORUS-SUBSTITUTED COMPOUNDS AS C-MET INHIBITORS AND THERAPEUTIC USES THEREOF | BETA PHARMA INC (US) | 2024-07-17 | — | — | EP | disclosed |
| EP-3893872-B1 | ORGANOPHOSPHORUS-SUBSTITUTED COMPOUNDS AS C-MET INHIBITORS AND THERAPEUTIC USES THEREOF | BETA PHARMA INC (US) | 2024-07-17 | — | — | EP | disclosed |
| CN-113412112-B | Organophosphorus substituted compounds as c-MET inhibitors and therapeutic uses thereof | 贝达医药公司 | 2024-06-11 | — | — | CN | disclosed |
| EP-3893872-A1 | ORGANOPHOSPHORUS-SUBSTITUTED COMPOUNDS AS C-MET INHIBITORS AND THERAPEUTIC USES THEREOF | Beta Pharma, Inc. (US) | 2021-10-20 | — | — | EP | disclosed |
| CN-113412112-A | Organophosphorus substituted compounds as c-MET inhibitors and therapeutic uses thereof | 贝达医药公司 | 2021-09-17 | — | — | CN | disclosed |
| WO-2020124060-A1 | ORGANOPHOSPHORUS-SUBSTITUTED COMPOUNDS AS C-MET INHIBITORS AND THERAPEUTIC USES THEREOF | BETA PHARMA, INC. (US) | 2020-06-18 | — | — | WO | disclosed |
| WO-2020124060-A1 | ORGANOPHOSPHORUS-SUBSTITUTED COMPOUNDS AS C-MET INHIBITORS AND THERAPEUTIC USES THEREOF | BETA PHARMA, INC. (US) | 2020-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12258365-B2 | Organophosphorus-substituted compounds as c-MET inhibitors and therapeutic uses thereof | MET, ALK, TYRO3 | FLT3 14/4885IRAK4 63/4885IRAK1 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.